cyrilzakka/clinical-trials huggingface dataset:
ANgiogenic Function at NOrmal TErm on Placenta

In vivo and ex vivo study of trophoblastic angiogenic trophoblastic function in placentas from normal pregnancies, at term

The objective of this study is to better understand the regulation of trophoblast expression of pro- and antiangiogenic factors such as placenta growth factor (PlGF) or Soluble FMS like tyrosin-kinase-1 (sFlt-1), and more particularly on human differentiated trophoblastic cells from "healthy" placentas. The measurement of the variation in gene and protein expression of placental angiogenic factors will provide a better understanding of their pathophysiology.

Secondary objectives are the study of trophoblastic differentiation and placental functions, and the study of the impact of chemical compounds on the biological functions of the placenta. To do this, these "healthy" placentas may be exposed to different factors that promote the occurrence of specific pregnancy pathologies such as pre-eclampsia and vascular intrauterine growth restriction (IUGR), caused by placental dysfunction. This will make it possible to test molecules and vector approaches targeted directly at the trophoblast, in order to consider therapeutic targets, which do not exist to date.

Eligibility Criteria:
Inclusion Criteria:

* Pregnancies with scheduled cesarean delivery \>37 weeks of amenorrhea:
* strictly normal pregnancies
* complicated pregnancies of gestational diabetes, insulin-treated or not
* complicated pregnancies due to pregnancy cholestasis
* spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI) pregnancies with or without oocyte donation

Exclusion Criteria:

* Patient's opposition
* Age \< 18 years old
* Women under the protection of justice
* Multiple pregnancy
* Known major fetal malformation
* Pre-eclampsia and intrauterine growth retardation
* Placental insertionnomaly
* Type 1 diabetes
* HIV-positive patient with HIV/hepatisis C virus (HCV) regardless of viral load
* Patient in labour at the time of Caesarean section
* Patient whose medical history results in medication being taken in pregnancy courses that may interfere with the biology of the trophoblast (immunomodulators in case of autoimmune diseases, anti-rejection drugs in case of transplant patients)
Abnormalities of B Lymphocytes During Systemic Lupus

Previous experimental data strongly suggest that B lymphocytes have intrinsic abnormalities during lupus in mice spontaneously affected by the disease. This study tries to define these abnormalities by looking at the gene expression profile of purified B lymphocytes from patients with non active systemic lupus , compared with the gene expression profile of purified B lymphocytes from healthy donnors.


Eligibility Criteria:
Inclusion criteria:

* non active systemic lupus

Exclusion criteria:

* immunosuppressive drugs
* more than 10 mg of prednisone per day
Breathomics in the Diagnosis and Prediction of Radiotherapy-Induced Oropharyngeal Mucositis in Head and Neck Tumors

Radiotherapy-Induced Oropharyngeal Mucositis (RIOM) is one of the most distressing side effects for patients with head and neck tumors during radiotherapy, requiring clinical physicians to manage it according to the severity of mucositis to alleviate symptoms and improve quality of life. However, traditional diagnosis of RIOM overly relies on subjective evaluation, lacks early sensitivity, and existing biomarker diagnostic methods suffer from insufficient efficacy, invasiveness, and inconsistent results. This study aims to explore the diagnostic and predictive value of exhaled breathomics in RIOM of head and neck tumors. By collecting exhaled breath samples from head and neck tumor patients undergoing radiotherapy and analyzing volatile organic compounds (VOCs) using breath detection technology, we aim to develop and validate a non-invasive diagnostic and predictive model based on exhaled breathomics. The study will identify specific VOCs as potential biomarkers, providing new tools for early diagnosis, timely prediction, and personalized treatment of RIOM.


Eligibility Criteria:
Inclusion Criteria:

* Voluntarily sign informed consent. Over 18 years of age. Histologically confirmed head and neck tumors, treated with radiotherapy or chemoradiotherapy.

ECOG PS Score: 0/1/2.

Exclusion Criteria:

* Lung disease such as lung cancer, tuberculosis, and lung infections. Inhalation anesthesia within 3 months. Inhalation medication within 3 months. Postoperative laryngeal cancer. Concurrent serious uncontrolled medical conditions such as unstable heart disease requiring treatment, poorly controlled diabetes mellitus (fasting blood glucose \> 1.5 x upper limit of normal).

Participation deemed inappropriate in the judgment of the investigator.
Evaluation of the Clinical and Radiological Outcome of Uncemented Femoral Stems According to Their Proximal Coating

Evaluation of the clinical and radiological outcome of uncemented femoral stems according to their proximal coating.

Retrospective study

On a large population of patients having undergone total hip arthroplasty, divided into two cohorts constituted according to the type of femoral stem implanted (with or without proximal coating by MectaGrip):

Primary objective: To compare between the two groups the radiological osseointegration of the stems five years after arthroplasty.

Secondary objectives: To compare between the groups

* The functional outcome of the arthroplasty
* The frequency of radiological abnormalities (stress shielding, osteolysis, periprosthetic fractures or cracks, periprosthetic ossifications)
* Frequency of complications

Eligibility Criteria:
Inclusion Criteria:

* Patient aged 18 years or older, having been informed of the research
* A patient with at least five years of uncemented total hip replacement implanted as a first-line procedure
* A patient who has been regularly monitored since surgery and for whom all clinical and radiological data are available at the five-year follow-up visit

Exclusion Criteria:

* Patient operated for revision
* History of femoral fracture (pre or per operative)
* Chronic treatment likely to affect calcium metabolism and ossification
* Patient under legal protection, guardianship or curatorship
* A patient who has indicated his or her opposition to the use of his or her medical data (by completing and returning the non-opposition form that will be sent to him or her).
Bumetanide vs. Furosemide in Cirrhosis

Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis.

Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.


Eligibility Criteria:
Inclusion Criteria:

* History of liver cirrhosis
* Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital

Exclusion Criteria:

* Allergy to bumetanide or furosemide
* Contraindication to diuretic administration (e.g. active bleeding, clinical suspicion of hepatorenal syndrome, hypotension)
* Incarcerated or in custody of law enforcement
* Diuretic ordered for purpose other than volume overload (e.g. hyperkalemia, continuation of home medication without clinical signs of volume overload)
* Inpatient admission not anticipated
* Not admitted to an inpatient hospital bed following initial evaluation in the emergency department
Trigger Finger Corticosteroid Injection With and Without Local Anesthetic

Steroid injection is the first line treatment for trigger finger. Steroid injection is sometimes mixed with a local anesthetic.

The treatment of trigger finger involves an injection of corticosteroid. Corticosteroid treats the underlying inflammatory pathology. Some surgeons add lidocaine with epinephrine as a local anesthetic with the injection. Lidocaine with epinephrine is associated with a burning sensation and may be the primary pain associated with the injection. We hypothesize that a corticosteroid injection without lidocaine with epinephrine will be less painful, and equally effective in treating trigger finger

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years old with trigger finger

Exclusion Criteria:

* Preference for open trigger finger release
* Not a candidate for corticosteroid injection
* Contraindication to lidocaine with epinephrine
Relationship Between Serum Vitamin D and Outcomes of Liver Transplantation in Cirrhotic Patients Undergoing Liver Transplantation and Effects of Vitamin D Supplementation in Post-transplant Period

The study population is patients with liver cirrhosis undergoing liver transplantation; In this study, the sample will be selected from cirrhosis patients undergoing liver transplantation in Taleghani (Tehran), Imam Khomeini (Tehran) and Abu Ali Sina hospitals(Shiraz).

This study uses the recorded information of patients with cirrhosis who have undergone liver transplantation so far and have inclusion criteria and no exclusion criteria. First, we extract demographic and clinical and pathophysiological information of patients, including age, sex, BMI, cause of cirrhosis, medical status at the time of liver transplantation, history of abdominal surgery, portal vein thrombosis, and waiting time for liver transplantation. In the next step, we examine the serum level of vitamin D in different age and sex groups and determine the prevalence of vitamin D deficiency for each group. It should be noted that in this study, the serum level of 25-hydroxy vitamin D below 20 ng/mL will be considered an insufficient level.

In the next step, in patients 12 years of age and older, according to serum bilirubin, serum creatinine, serum sodium and INR, we calculate the MELD-Na score and evaluate it with the serum level of vitamin D or 25-hydroxy vitamin D. We also use PELD scores in patients younger than 12 years of age, which consist of age, serum albumin, total bilirubin, INR, and stunted growth.

Follow-up will be done by calling the patients and recruitment every 3 month. ACR or acute cell rejection is usually suspected after elevated liver enzymes (serum aminotransferases, alkaline phosphatase, gamma glutamyl transpeptidase) or bilirubin (30). The incidence of ACR and Overall survival (OS) will be considered as the end point of the first phase of the study, and finally the incidence of 25-hydroxy vitamin D before transplantation with MELD-Na or PELD score will be examined. ACR and OS, we deal with statistical tests.

In the second phase of the study, which is a clinical trial, 50 sample patients with vitamin D deficiency will be selected from Taleghani Hospital; After transplanting, we will inject 300,000 units of vit D IM and compare their ACR and OS levels with those who have been deficient in vitamin D but whose vitamin D status has not improved. It is worth mentioning that in the second phase of the study, patients will be followed up to 3 months after liver transplantation.


Eligibility Criteria:
Inclusion Criteria:

* ESLD underwent liver transplantation
* Creatinine, bilirubin and INR measured
* Measured liver enzymes such as serum aminotransferases, alkaline phosphatase, gamma glutamyl transpeptidase / or bilirubin

Exclusion Criteria:

* People with acute liver failure
* People who have had multiple organ transplants
* Primary graft non-function (PNF) individuals
Cardiovascular Responses to Spartathlon Running

The aim of this study is to examine the cardiovascular effects of ultramarathon running and their relation to performance.

The purpose of the study is to determine the changes of cardiovascular morphology and function after an ultramarathon race. 50 entrants to the "Spartathlon 2017" 246-km running race will participate in the study. Cardiac and arterial morphology and function tests will be conducted one day before the race and within 20 minutes of race completion.

Eligibility Criteria:
Inclusion Criteria:

* Runners at least 18 years old, healthy and sufficiently trained.
* Runners being accepted to participate in the Spartathlon race according to the eligibility criteria (http://www.spartathlon.gr/en/registration-en.html)
* Runners who will volunteer to be examined pre- and post the race

Exclusion Criteria:

* Runners with chronic diseases
* Runners receiving any medication
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI.

The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study.

Up to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).


Eligibility Criteria:
Inclusion Criteria:

* History of acute head injury with or suspected non-penetrating acute TBI
* Suitable to undergo contrast-enhanced MRI
* Negative serum pregnancy test

Exclusion Criteria:

* Inability to undergo MRI scan
* Inability to receive IV MRI contrast agents secondary to severe reaction or renal insufficiency
* Positive pregnancy test
Tadalafil Daily Used Post Turp

to assess the effect of early tadalafil 5 mg once daily on persistent storage lower urinary tract symptoms (LUTS) and erectile function after transurethral resection of the prostate (TURP).


Eligibility Criteria:
Inclusion Criteria:

* sexual active men

Exclusion Criteria:

* sexual inactive men
* cardiac patients
Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan

Abatacept Registry in Taiwan


Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* ≥ 20 years of age
* Who give informed consent
* Confirmed diagnosis of RA (as defined by American College of Rheumatology revised 1987 criteria) and has ≥ 4 of the criteria listed below for ≥6 weeks before study enrollment
* Who self-pay or who are reimbursed by BNHI for abatacept treatment
* With latent TB or who are receiving anti-TB treatment (INH 300 mg, QD) 1 month prior to using abatacept and continuously up to a total of 9 months Willing to follow Taiwan Risk Management Plan guidelines as required by Taiwan health authorities
* Are being treated with abatacept or are abatacept treatment naïve and are initiating abatacept therapy

Exclusion Criteria:

* Pregnant or breast feeding
* With active TB
* HBsAg (+)and/or Anti-HCV(+) and/or HBV DNA(+)
* Have cancer (patients who were treated and have no sign of cancer for \> 10 years can be included)
* Are allergic to abatacept
* Enrolled in other RA clinical studies
Quality of Life After Conservative and Surgical Treatment of Pelvic Organ Prolapse

This is an observational study that gives baseline and follow-up information, that does not directly influence the allocation of patients to various treatment Options (conservative and surgical therapy of Pelvic Organ Prolapse) but the knowledge gained of the data will help to develop treatment strategies.


Eligibility Criteria:
Inclusion Criteria:

- Pelvic Organ Prolapse (POP)

Exclusion Criteria:

* \< 18 years
* Patients unable to understand an informed consent
* Patients unwilling to participate
* emergency operations
* pregnancy
* Overactive Bladder without descensus
* Stool incontinence without POP
App-based Education Program for CKD

A randomized control trial to test the effect of a mobile app-based educational program for Chronic Kidney Disease patients.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with CKD Stage 1\~5
* Have been receiving CKD treatment for more than 6 months
* Owns an android mobile phone

Exclusion Criteria:

* Diagnosed with cancer within 5 years of recruitment
Immune Profiles Evolution Under Immunotherapy for Melanoma

The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association of these immune profiles with relapse- or progression-free survival.

This study will analyse the association of biomarkers with relapse- or progression-free survival of stage III or IV melanoma patients, divided in 3 sub-cohorts:

* Patients treated in the adjuvant setting (cohort A): new user of immune checkpoint blockers.
* Patients treated in the metastatic setting (cohort B): - B1: new users of immune checkpoint blockers; - B2: prevalent users of immune checkpoint blockers treated with complementary radiotherapy.

For patients of cohort A and B1, immune profiles characteristics will be evaluated before initiation of treatment (=baseline), and at each radiological evaluation of the tumour response, up to maximum 12 months as duration.

The maximal duration of treatment will be 12 months for patients treated in the adjuvant setting. For metastatic patients, the duration of treatment will be decided by physician according to different factors (responses, progression, toxicities, ...).

For patients in cohort B2, the characteristics of the immune profiles will be evaluated before radiotherapy initiation,, within 6 weeks after the end of radiotherapy, then at the 2 following radiological evaluations of the tumour response

Eligibility Criteria:
Inclusion Criteria:

* Patient aged ≥ 18 years;
* Totally resected stage III or IV melanoma totally resected, treated with a immune therapy (pembrolizumab or nivolumab ou other immune checkpoint inhibitors) as adjuvant treatment;
* Unresectable stage IIIC/D or IV metastatic melanoma, treated with immune therapy (pembrolizumab or nivolumab or immune checkpoint inhibitors) which should be associated by a radiotherapy ;
* Patient has been informed about the study and signed the consent;
* Affiliated to the French social security scheme.

Exclusion Criteria:

* Pregnant or breastfeeding woman;
* Patient refusal;
* Patient receiving a immunosuppressor;
* Undergo a general corticotherapy of \> 10 mg/kg/day since more than 7 days;
* Patient who participate to another blind interventional study receiving blinded treatment;
* Patient without any social protection by organization.
Feasibility of Specific Anesthesia of the Forefoot Preserving the Sensitivity of the Heel for Foot Surgery

Foot surgery is a painful surgery that is usually scheduled in outpatients. A good management of analgesia is the crucial point. Regional anesthesia (RA) is the gold standard, that provides good anesthesia and a long duration of analgesia. The sciatic nerve block (or its branches) is the most adapted analgesic technique.

Limitation of proximal sciatic block is the motor block of the ankle and results in the impossibility, for the patient, to walk during the early post-operative period. Distal block of the sciatic nerve (tibial and fibular nerve blocks), at the level of the ankle, has been proposed to maintain the mobility of the ankle, to make deambulation with crutches easier. Nevertheless, the lack of sensibility of the heel remains a limitation for early walking, even with adapted shoes (ie : Barouk).

A specific anesthesia of the distal part of the foot, respecting the heel, could be the best option to provide an early deambulation and a suitable analgesia.

Ultrasound identification and specific anesthesia of the branches supplying the distal part of the foot (medial and lateral plantar nerves) could meet this dual objective : good anesthesia and suitable analgesia for early deambulation.

This study is a feasibility study of a specific block of the plantar branches of the tibial nerve, to preserve the sensibility of the heel, in case of foot surgery. The safety of the procedure will be assessed according to the rate of postoperative dysesthesia.

Block of the medial and lateral plantar branches of the tibial nerve will be performed under the medial malleolar-calcaneal axis (MMCA) in order to preserve the calcaneal nerves.

Blocks of the deep peroneal nerve (DPN) and the superficial peroneal nerve (SPN) will be added to provide an adequate anesthesia.

Every block will be performed under Ultrasound using a 27-gauge, 5-cm, short bevel needle.

5 mL of 0.375% Ropivacaine will be injected for each block. The sensory blocks will be assessed by pinprick test and cold test every 10 minutes for 40 minutes in the following locations: Calcaneal nerves, Lateral plantar nerve and Medial plantar nerve.

The extent of sensory block will be graded as follows: 2: normal sensation; 1: decreased sensation; and 0: no sensation (complete block).

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing a foot surgery
* Consent for participation
* Affiliation to the french social security system

Exclusion Criteria:

* Patient's refusal
* Existence of major spontaneous or acquired haemostatic disorders
* Infection at the point of puncture
* Allergy to local anesthetic or analgesic
* Pregnant or likely to be pregnant
* Patients under protection of the adults (guardianship, curator or safeguard of justice)
* Patients whose cognitive state does not allow assessment by the scales used
* Neuropathic disease
Standardized Emergency Care for Community Acquired Pneumonia (CAP)

Community acquired pneumonia (CAP) is associated with a high in-hospital mortality. Standardization of diagnostics and adherence to sepsis bundles in the emergency department (ED) are associated with reduced mortality in patients with sepsis. Investigators examined whether the introduction of standardized care bundles and check lists in the ED are associated with a reduced mortality rate in patients hospitalized for CAP.

This is an observational trial. The investigators retrospectively analyzed performance indicators of 2819 consecutive patients with CAP admitted to the Nuremberg Hospital, Germany, from 2008 to 2009. At the turn of the year, implementation of CAP care bundles took place including interprofessional education, checklists and institutionalized feedback. Primary endpoint was in-hospital mortality of CAP patients. After the implementation of CAP care bundles in the ED, mortality of affected patients was significantly lower in 2009 compared to 2008. This study should demonstrate that the implementation of a standardized CAP care bundle in the ED is associated with a risk reduction in affected patients. Standardization of diagnostic and therapeutic processes in the ED therefore improves the outcome of patients hospitalized for CAP.


Eligibility Criteria:
Inclusion Criteria:

* all patients with community acquired pneumonia

Exclusion Criteria:

* exacerbation of chronic obstructive pulmonary disease
* malignancy
* immunosuppression
* neutropenia